Summary:
Test the efficacy of the research study drug, mk-1602 vs placebo in patients with moderate to severe migraines. There will be 3 visits. If qualified, a screening visit will occur and you will be sent home with the study medication or a placebo (a sugar pill) within a 2 month time period if you have a migraine you will take the study medication. If the study medication does not control the pain, your regular migraine medication can be taken 2 hours after migraine onset. You will come to the study site for two more visits after study drug consumption.
Qualified Participants Must:
• Be between 18 and 65 years of age
•
Have at least a 1 year history of migraines
•
Have migraines that typically last between 4 to 72 hours, if untreated
•
Have 2 - 8 moderate or severe migraine attacks per month in each of the two months prior to screening
•
Have no more than 15 headache-days per month or have taken medication for acute headache on more than 10 days per month in any of the three months prior to screening
•
Be taking migraine prophylactic medication where the prescribed daily dose has not changed during the 3 months prior to screening and will not be changed during the study
•
Have no history of gastric or small intestinal surgery (including gastric bypass surgery or banding), or presence of a disease that causes malabsorption
•
No use of opioid- or barbiturate-containing analgesic within the past 2 months of an for migraine relief
•
No emergency room treatment of an acute migraine attack within the past 2 months
Qualified Participants May Receive:
Migraine medication or placebo, $50.00 for every completed visit, lab work, EKGs, gel Ice pack face mask, timer for timing migraines and a tote bag.